Sarepta Stock Soars. Why Layoffs and a ‘Black-Box’ Warning Are Good News. - Barron's
1. Sarepta stock surged over 30% following a major workforce layoff. 2. Adding a black-box warning may alleviate FDA approval concerns. 3. Cost-cutting measures aim for $400 million in annual savings. 4. Analyst suggests Elevidys updates are positive despite patient deaths. 5. Sarepta is projected to incur losses in 2025.